Growth hormone-releasing peptide blend
CJC-1295 + Ipamorelin
A vial of CJC-1295 (no DAC) and ipamorelin. None of the 11 PubMed records naming both, in a title-or-summary search of 16 November 2026, reports a trial of the two given together.
CJC-1295 + Ipamorelin after one dose: 50% at ~1.25 h, 25% at 2.5 h, 12.5% at 3.75 h.
Drawn from the half-life in the app's model, ~1.25 h. The model's figures
- Compound
- CJC-1295 + Ipamorelin
- Symbol
- C+I
- Family
- Growth hormone peptides
- Parts
- 14
- References
- 23
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

4%The 14th most tracked compound in Milligram: of people who track compounds in Milligram logged CJC-1295 + Ipamorelin in the last 90 days.
Schedule
Logged doses
Half of people logged between 200 and 500 mcg per dose; the median was 300 mcg.
Tracked alongside
The share of people logging CJC-1295 + Ipamorelin who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
Sources in this part
CJC-1295 + Ipamorelin is, in the app, a pre-mixed vial of CJC-1295 (no DAC) 5 mg and ipamorelin 5 mg, 10 mg in total.
CJC-1295 is described in a 2026 review as "a synthetic analogue of GHRH, designed to stimulate pituitary GH secretion", where GHRH is growth hormone-releasing hormone and GH is growth hormone.1 Ipamorelin is described in another review as "a synthetic pentapeptide that is a selective agonist of the ghrelin/ GHS receptor pathway".2
A search of PubMed on 16 November 2026 for CJC-1295 and ipamorelin together in the title or summary text returned 11 records: ten review articles, all from 2026, and a 2013 study of doping control analysis in horse plasma. None of the 11 reports a trial of the two given together.
The app grades the evidence for the blend as moderate, and that grade is the app's. A 2026 review states that "the best human evidence comes from randomised, placebo-controlled, double-blind ascending-dose trials conducted in healthy adults using CJC-1295 DAC administered subcutaneously", while "CJC-1295 without DAC" "remains essentially uncharacterised in the peer-reviewed human literature".1 The blend in the app uses the no-DAC form.
How it works
CJC-1295
Jetté and colleagues of ConjuChem Inc. described CJC-1295 in Endocrinology in 2005 as "a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus".3 In normal male Sprague Dawley rats given it subcutaneously, it "showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29)", and the authors report it in plasma beyond 72 hours.3
A 2026 review describes two variants: CJC-1295 with a drug-affinity complex (DAC), in which "the DAC modification enables binding to circulating albumin, markedly prolonging exposure", and CJC-1295 without DAC.1 The app's blend lists the no-DAC form, and the app's notes for that form call it Mod GRF 1-29. The 2026 review also uses the name Mod GRF 1–29 for CJC-1295 without DAC.1
Ipamorelin
Raun and colleagues of Novo Nordisk described ipamorelin in the European Journal of Endocrinology in 1998 as a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that stimulates GH release "via a GHRP-like receptor".4 The authors report that ipamorelin "did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation", while GHRP-6 and GHRP-2 increased ACTH and cortisol in the same swine experiment.4 These are rat, swine and cell results.4
The two together
Dominikowski and colleagues write in Frontiers in Endocrinology in 2026 that "in off-label fitness discourse, ipamorelin is also frequently discussed in combination with CJC-1295 (typically the non-DAC form) to amplify GH release through complementary stimulation of the GH axis", and that "this practice is largely driven by anecdotal rationale, and controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited".1
Rahman and colleagues state in a 2026 review: "In combination, ipamorelin and CJC-1295 without DAC (also known as Modified GRF) exhibit a synergistic effect, elevating both GH and IGF-1 levels in a pulsatile, physiologic manner".5 The review puts the number 28 after that sentence, and its reference 28 is Stanley and colleagues' 2011 trial of tesamorelin 2 mg subcutaneously once daily for 2 weeks in 13 men, a different GHRH analog.5,6 In its summary the same review says of the peptides it covers, which include ipamorelin and CJC-1295: "Although preclinical studies are promising, there is a current lack of clinical trials".5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.25 h
- Bioavailability
- 95%
- Typical dose
- 200–600 mcg/day
- Route
- SubQ
- Time to peak
- ~15 min
The table sets the app's figures for the blend beside what the sources cited report for each peptide alone. None of the sources cited reports a pharmacokinetic measurement of the two peptides given together.
| Parameter | App's figure for the blend | Reported in the sources for each peptide alone |
|---|---|---|
| Half-life | About 1.25 hours | Not reported for the blend. Ipamorelin: a terminal half-life of 2 hours after 15-minute infusions in healthy men.7 CJC-1295 as tested by Teichman and colleagues, a figure the 2026 review lists under the DAC form: an estimated half-life of 5.8 to 8.1 days after subcutaneous injection.8,1 CJC-1295 without DAC: a 2026 review's table lists its half-life as not reported in human studies, and the review states that no controlled clinical study has directly evaluated it.1 |
| Other half-life figures | Not given by the app | None has a measurement of its own in the record cited. CJC-1295, albumin-binding form: "half-life = 8 d" (Ionescu and Frohman),10 "8 – 10 days in humans" (Sackmann-Sala and colleagues)11 and "6–8 days" (Mavrych and colleagues).19 Ipamorelin: "1.5–2.5 h" subcutaneously (Sinha and colleagues)2 and "~ 2h" (the 2026 review).1 |
| Time to peak | About 15 minutes | Not reported for the blend. After ipamorelin infusions in healthy men, GH release peaked at 0.67 hours.7 |
| Bioavailability | 95% by subcutaneous injection | No subcutaneous figure for either peptide appears in the sources cited. After intranasal ipamorelin in the male rat, the bioavailability was estimated at approximately 20%.9 |
Human studies
The table lists human studies of each peptide alone, with the registry entries for two further trials. No row gave CJC-1295 and ipamorelin together.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Teichman and colleagues, 2006 (CJC-1295)8 | Two randomized, placebo-controlled, double-blind, ascending-dose trials of 28 and 49 days at two investigational sites | Healthy adults aged 21 to 61; the number is not in the record's text | CJC-1295 or placebo subcutaneously: one of four ascending single doses in the first trial; two or three weekly or biweekly doses in the second | After a single injection, dose-dependent increases in mean plasma GH of 2- to 10-fold for 6 days or more and in mean IGF-I of 1.5- to 3-fold for 9 to 11 days; no serious adverse reactions were reported. |
| Ionescu and Frohman, 2006 (CJC-1295)10 | GH sampled every 20 minutes over 12 overnight hours, before and 1 week after one injection | Healthy men aged 20 to 40; the number is not in the record's text | 60 or 90 microg/kg CJC-1295, one injection | GH pulse frequency and magnitude were unaltered; trough GH rose 7.5-fold (P < 0.0001), mean GH levels 46% (P < 0.01) and IGF-I 45% (P < 0.001); the two doses did not differ significantly; the IGF-I increases did not correlate with any parameters of GH secretion. |
| Gobburu and colleagues, 1999 (ipamorelin)7 | Dose-escalation trial with 5 infusion rates, 8 healthy men at each dose level | Healthy male volunteers | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes | Dose-proportional pharmacokinetics with a terminal half-life of 2 hours; a single episode of GH release peaked at 0.67 hours. |
| Beck and colleagues, 2014 (ipamorelin)12,13 | Phase 2, multicenter, double-blind, placebo-controlled trial in postoperative ileus | 117 adults enrolled after small or large bowel resection; 114 in the safety and modified intent-to-treat populations, which Sinha and colleagues report as 56 given ipamorelin and 58 given placebo2 | 0.03 mg/kg ipamorelin or placebo by intravenous infusion twice daily, postoperative day 1 to 7 or hospital discharge | Median time to first tolerated meal 25.3 h with ipamorelin and 32.6 h with placebo (p = 0.15); any treatment-emergent adverse event 87.5% with ipamorelin and 94.8% with placebo; no significant differences in the key and secondary efficacy analyses. |
| Registry entry NCT01280344 (ipamorelin), 2011 to 201414 | Phase 2, randomized, double-blind, placebo-controlled dose-finding trial after bowel resection | 320 enrolled; Helsinn Therapeutics (U.S.), Inc is the lead sponsor | 0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily, intravenous | The record shows the study as completed and has no results posted. |
| Registry entry NCT00267527 (CJC 1295), 2005 to 200615 | Phase 2, randomized, placebo-controlled, double-blind; 12 weeks of treatment and a 6 week follow-up | 120 listed; HIV-infected patients with HIV-associated visceral obesity; ConjuChem is the lead sponsor | Low dose CJC 1295, high dose CJC 1295 or placebo; the doses are not given in the record | The record shows the study as terminated, gives no reason and has no results posted. |
Deeper analysis: Teichman and colleagues, 2006, and Ionescu and Frohman, 2006
Teichman and colleagues report two trials of CJC-1295 in healthy adults, in the Journal of Clinical Endocrinology and Metabolism in 2006. The main outcome measures were "peak concentrations and area under the curve of GH and IGF-I", and the authors state that after multiple doses "mean IGF-I levels remained above baseline for up to 28 d".8 They conclude that CJC-1295 "was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg".8
Three of the six authors (Lawrence, Gagnon and Castaigne) are affiliated with ConjuChem, Inc., two (Teichman and Neale) with WinPharm Associates and one (Frohman) with the University of Illinois.16 ConjuChem is the lead sponsor of the registered phase 2 trial of CJC 1295 in HIV-associated visceral obesity.15 The PubMed record of the 2006 trial gives no funding statement and does not list the authors' own limitations; its publication types include "Research Support, Non-U.S. Gov't".8
Ionescu and Frohman of the University of Illinois at Chicago conclude that "CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility".10 The PubMed record lists an NIH grant (M01-RR-13987) and no limitations, and does not give the number of men.10 Sackmann-Sala and colleagues of Ohio University drew 11 men from a larger cohort described in their reference 8, the Ionescu and Frohman paper, and report that their work was supported in part by "grants from WADA, the Diabetes Research Initiative at Ohio University, and ConjuChem Inc.".11
Deeper analysis: Gobburu and colleagues, 1999
Gobburu and colleagues, with a first-author affiliation at the State University of New York at Buffalo, gave eight healthy men at each of five dose levels an ipamorelin infusion over 15 minutes and measured ipamorelin and GH.7 Ipamorelin "induces the release of GH at all dose levels", and the authors note that "the inter-individual variability of the PD parameters was larger than that of the PK parameters".7 The PubMed record gives no funding statement.7
Deeper analysis: Beck and colleagues, 2014
Beck, of the Ochsner Clinic Foundation, and colleagues report a phase 2 trial of ipamorelin in postoperative ileus in the International Journal of Colorectal Disease in 2014, registered as NCT00672074.12 The trial found no significant difference from placebo in median time to first tolerated meal (p = 0.15), and the authors conclude that "Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated".12 The authors state: "This study was supported by Helsinn Therapeutics (US), Inc.", that their institutions "received grants from Helsinn Therapeutics (US), Inc., to conduct the study", and that they "declare no financial or proprietary conflicts of interest".12 Helsinn also supported the manuscript's development and is the registry's lead sponsor.12,13
The authors' own stated limitation is that "this proof of concept study was small and enrolled patients with a broad range of underlying conditions".12 The summary text reports no deaths or discontinuations, and the registry entry for the same trial has no results posted.12,13
Animal studies and statements about the pair
Alba and colleagues gave 1-week-old growth hormone-releasing hormone knockout mice 2 microg of CJC-1295 at intervals of 24, 48 or 72 hours for 5 weeks.17 Daily doses produced "normal body weight and length", while mice treated every 48 or 72 hours "reached higher body weight and length than placebo-treated animals, without full growth normalization".17 Relative lean mass and subcutaneous fat mass were normal in all treated groups, and total pituitary RNA and GH mRNA increased, "suggesting that proliferation of somatotroph cells had occurred".17 Two authors, Lawrence B and Castaigne JP, share names with ConjuChem-affiliated authors in the Crossref record of Teichman and colleagues' trial; PubMed gives the first author's affiliation only and no funding statement, so a tie is not confirmed.17,16
Mayfield and colleagues write in the American Journal of Sports Medicine in 2026 that "CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies".18 A search of PubMed on 16 November 2026 for ipamorelin with a glucocorticoid or dexamethasone term and a muscle term returned 2 records, the Mayfield review and a 2001 rat study of ipamorelin and bone formation; neither is a murine study of the pair, so the study behind the review's sentence was not among them. Mavrych and colleagues repeat the sentence in Frontiers in Aging in 2026.19
Doses reported in studies
No dose of the two peptides together from a study is reported in the sources cited. The app lists a typical dose of 200 to 600 mcg per day for the blend by subcutaneous injection, which is the app's figure and not a dose from a study.
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Teichman, 2006 (CJC-1295, subcutaneous)8 | One of four ascending single doses in the first trial; the conclusion names doses of 30 or 60 microg/kg | Two or three weekly or biweekly doses in the second trial | 28 and 49 days |
| Ionescu and Frohman, 2006 (CJC-1295; route not stated in the record's text)10 | 60 or 90 microg/kg | One injection | Samples taken before and 1 week after the injection |
| Sackmann-Sala, 2009 (CJC-1295, subcutaneous)11 | 60-90 microg/kg | A single injection | Sera taken before and 1 week after the injection |
| Gobburu, 1999 (ipamorelin)7 | 4.21 to 140.45 nmol/kg over 15 minutes; the route is not stated in the record's text, and the 2026 review lists "IV infusion"1 | Not stated in the record's text; the 2026 review lists "single administration"1 | Infusions of 15 minutes |
| Beck, 2014 (ipamorelin, intravenous)12 | 0.03 mg/kg | Twice daily | Postoperative day 1 to 7 or hospital discharge |
Side effects reported
No trial of the two peptides together is among the records the searches returned, so no side effects of the pair are reported in them. Teichman and colleagues state for their two CJC-1295 trials that "no serious adverse reactions were reported", and in the ipamorelin trial of Beck and colleagues any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group.8,12
A 2026 review's table for CJC-1295 with DAC lists "no serious adverse events reported at tested doses; mild local and systemic effects related to GH axis stimulation have been observed".1 For the class of peptides it reviews, which includes CJC-1295 and ipamorelin, the same review lists reported adverse effects of prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention syndromes, myalgia or arthralgia, and injection-site reactions; the list is not specific to the pair.1 A 2026 scoping review of six peptides, including CJC-1295, ipamorelin and MK-677, states that "Documented risks include cardiovascular complications and metabolic dysfunction such as insulin resistance", and that MK-677 was associated with congestive heart failure.23
Statements by regulators
FDA's category 2 page says of CJC-1295: "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited".20 For ipamorelin it says: "A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility", and that it "has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration".20 The page does not name the published study.20
Mavrych and colleagues write that CJC-1295 "showed promise in Phase 2 trials, but commercial development ceased following a trial participant's death, though it was deemed unrelated to the study drug".19 The review's reference for that sentence is Teichman and colleagues, 2006, whose summary text reports no serious adverse reactions.19,8 The registry entry for ConjuChem's phase 2 trial shows it as terminated, with no reason given.15
The Australian TGA's April 2026 advisory says of unapproved peptide products in general that it has received reports including "severe allergic reactions, requiring doses of adrenaline and hospitalisation", and that CJC-1295 is among its examples of such products.21
Bloodwork and markers
The app lists IGF-1, blood glucose and insulin as markers. In the CJC-1295 trials the measured outcomes were GH and IGF-I, and Sackmann-Sala and colleagues suggest that the serum proteins they identified "represent potential biomarkers of GH and/or IGF-1 action".8,11 The summary texts of the CJC-1295 and ipamorelin studies in the human studies table do not mention blood glucose or insulin.
Stanley and colleagues, in the Journal of Clinical Endocrinology and Metabolism in 2011, gave 13 men tesamorelin, a different GHRH analog, and report that "Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin"; this is not a measurement of either peptide in the blend.6 The 2026 review's table of signals across GH-IGF-1-axis peptides gives for dysglycaemia and insulin resistance in GHRH analogues the note "tesamorelin: no major signal; GH-excess analogy".1
Regulatory and anti-doping status
Dominikowski and colleagues write that "neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities (e.g., FDA, EMA)".1 The table gives each peptide's entry on FDA's category 2 page and in the WADA 2026 Prohibited List.
| Peptide | FDA category 2 page (content current as of 22 April 2026) | WADA 2026 Prohibited List |
|---|---|---|
| CJC-129520,22 | Listed under "Bulk drug substances nominated but withdrawn", a list FDA describes as substances "previously in category 2 of the interim policies" that were "withdrawn by the nominators"; compounded drugs containing CJC-1295 "may pose risk for immunogenicity for certain routes of administration". | Named as an example ("e.g.") in S2.2.4, with CJC-1293, among growth hormone-releasing hormone analogues; class S2 is prohibited at all times, in and out of competition. |
| Ipamorelin20,22 | Category 2 under the 503B interim policy, added 29 September 2023: compounded drugs containing ipamorelin acetate "may pose risk for immunogenicity for certain routes of administration". | Named as an example in S2.2.4 among growth hormone secretagogues and their mimetics; class S2 is prohibited at all times, in and out of competition. |
The WADA list states that "all prohibited substances in this class are non-Specified Substances".22 The Australian TGA's safety advisory of 13 April 2026 states that unapproved peptide products "have not been assessed by the TGA for safety, quality or effectiveness" and names CJC-1295 among its examples.21
What is not known
How the two peptides behave when mixed in one vial or given together, including absorption, clearance, GH response and tolerability, is not described in the 11 records the searches returned, none of which reports a trial of the pair.1
None of the three registry entries (NCT00672074, NCT01280344, NCT00267527) has results posted.13,14,15 A 2026 scoping review of 6 peptides, including CJC-1295 and ipamorelin, for musculoskeletal recovery and performance states that "human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs".23
Frequently asked questions
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is, in the app, a pre-mixed vial of CJC-1295 (no DAC) 5 mg and ipamorelin 5 mg, 10 mg in total.
What is the half-life of CJC-1295 + Ipamorelin?
What is the half-life of ipamorelin?
Ipamorelin had a terminal half-life of 2 hours in the one human pharmacokinetic study cited, in which 8 healthy men at each of 5 dose levels received 15-minute infusions.7
What is the half-life of CJC-1295?
CJC-1295 as tested by Teichman and colleagues, a figure the 2026 review lists under the DAC form, had an estimated half-life of 5.8 to 8.1 days after subcutaneous injection in healthy adults.8,1 For CJC-1295 without DAC, the app lists 0.5 hours, and a 2026 review's table lists its half-life as not reported in human studies.1
What is the difference between CJC-1295 with DAC and without DAC?
The DAC modification "enables binding to circulating albumin, markedly prolonging exposure", according to a 2026 review, which calls the form without DAC "essentially uncharacterised in the peer-reviewed human literature".1
Has CJC-1295 been studied together with ipamorelin?
A search of PubMed on 16 November 2026 for both names in the title or summary text returned 11 records, and none reports a trial of the two given together. Ten are review articles from 2026, one of which states that CJC-1295 combined with ipamorelin "showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies".18
Is CJC-1295 + Ipamorelin banned by WADA?
The WADA 2026 Prohibited List names CJC-1295 and ipamorelin as examples in section S2.2.4, under class S2 headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", in the World Anti-Doping Code International Standard that applies to athletes under that Code.22 The list was in effect from 1 January 2026.22
Is CJC-1295 + Ipamorelin approved by the FDA?
None of the sources cited describes an FDA approval of either peptide, and a 2026 review states that neither CJC-1295 variant is approved as a therapeutic agent by major regulatory authorities such as FDA and EMA.1 FDA's category 2 page lists CJC-1295 as a bulk drug substance "previously in category 2" that was withdrawn by its nominators, and ipamorelin acetate as category 2 under the 503B interim policy.20
What are the side effects of CJC-1295 + Ipamorelin?
No trial of the pair is among the 11 records from the search of 16 November 2026, so none reports side effects of the pair. Teichman and colleagues' two CJC-1295 trials reported no serious adverse reactions.8 A 2026 review states that CJC-1295's commercial development "ceased following a trial participant's death, though it was deemed unrelated to the study drug", and the registry entry for ConjuChem's phase 2 trial shows it as terminated with no reason given.19,15 FDA's category 2 page cites serious adverse events associated with CJC-1295 and a published study of intravenous ipamorelin with serious adverse events including death.20
Guides, tools and comparisons
- CJC-1295 and ipamorelin dosageA guide that answers a question on this compound.
- Calculator for CJC-1295 + IpamorelinA calculator set up for this compound.
- Previous in Growth hormone peptides: CJC-1295 (no DAC)The compound before this one in the class.
- Next in Growth hormone peptides: CJC-1295 with DACThe compound after this one in the class.
References
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026. PMC13322892
- Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 2020. PMC7108996
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev 2026. PMC12753158
- Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011. PMID 20943777
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
- Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998. PMID 9879640
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006. PMID 17018654
- Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009. PMC2787983
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. Springer page
- Helsinn Therapeutics (U.S.), Inc. A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients. ClinicalTrials.gov NCT00672074. NCT00672074
- Helsinn Therapeutics (U.S.), Inc. Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis. ClinicalTrials.gov NCT01280344. NCT01280344
- ConjuChem. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity. ClinicalTrials.gov NCT00267527. NCT00267527
- Crossref. Publisher record of author affiliations for Teichman SL, et al., J Clin Endocrinol Metab 2006 (DOI 10.1210/jc.2005-1536). Crossref record
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006. PMID 16822960
- Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med 2026. PMID 41476424
- Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging 2026. PMC13095733
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. FDA category 2 page
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. TGA safety advisory
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med 2026. PMID 42578445